Evidence map›Paper›PMID 33211601›Full record

ArticleJournal of applied physiology (Bethesda, Md. : 1985)2021

Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction.

Kanokwan Bunsawat, Stephen M Ratchford, Jeremy K Alpenglow, Soung Hun Park, Catherine L Jarrett, Josef Stehlik, Adam S Smith, Russell S Richardson, D Walter Wray

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of applied physiology (Bethesda, Md. : 1985), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. When it's time for the sex talk, words matter.American journal of physiology. Heart and circulatory physiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kanokwan BunsawatDivision of Geriatrics, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-5950-6634
Stephen M RatchfordDivision of Geriatrics, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-6300-7600
Jeremy K AlpenglowDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah.
Soung Hun ParkDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah.
Catherine L JarrettDivision of Geriatrics, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-5131-7858
Josef StehlikDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
Adam S SmithDepartment of Pharmacy Services, University of Utah, Salt Lake City, Utah.
Russell S RichardsonDivision of Geriatrics, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
D Walter WrayDivision of Geriatrics, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
University of Utah · US

Funding

Peripheral Vasoconstriction in Heart Failure: Mechanisms & Modulatory InfluencesR01HL118313 · NHLBI · UNIVERSITY OF UTAH · PI WRAY, D. WALTER · 2014 to 2018
$1.9M
Cardiovasomobility Research Training ProgramT32HL139451 · NHLBI · UNIVERSITY OF UTAH · PI SUPIANO, MARK A, WRAY, D. WALTER · 2018 to 2022
$1.4M
Exercise and Cognitive Function in Alzheimers Disease Progression: Role of the Vascular EndotheliumR56AG057584 · NIA · UNIVERSITY OF UTAH · PI RICHARDSON, RUSSELL S. · 2018 to 2018
$658k
Overcoming Exercise Intolerance in Veterans with Heart Failure: The Role of NO.I01RX001311 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI WRAY, D. WALTER · 2017 to 2020
–
American Heart Association-American Stroke Association 18POST33960192NHLBI NIH HHS R01 HL118313NHLBI NIH HHS T32 HL139451NIA NIH HHS R56 AG057584RRD VA I01 RX001311VA E1433-PVA E1572-PVA E1697-RVA E6910-RVA E9275-LVA RX001311
6 · The paper itself

Abstract

The Prospective comparison of ARNI with angiotensin-converting enzyme inhibitor to Determine Impact on Global Mortality and morbidity in Heart Failure trial identified a marked reduction in the risk of death and hospitalization for heart failure in patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril-valsartan (trade name Entresto), but the physiological processes underpinning these improvements are unclear. We tested the hypothesis that treatment with sacubitril-valsartan improves peripheral vascular function, functional capacity, and inflammation in patients with HFrEF. We prospectively studied patients with HFrEF (

Indexed as

Heart FailureAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsHumansInflammationProspective StudiesStroke VolumeTetrazolesTreatment OutcomeValsartanVentricular Function, LeftAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanEntrestoflow-mediated dilationheart failurereactive hyperemia

Identifiers

PMID33211601
PMCPMC7944927
OpenAlexW3103044403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.